drugset / Trial / NCT00785928
A Study for Patients With Active Rheumatoid Arthritis Despite Ongoing Methotrexate Therapy
RandomizedParallel-groupQuadruple-blindTreatment
Summary
To assess the efficacy of LY2127399 versus placebo using American College of Rheumatology (ACR)50 response scale at 24 weeks
Timeline
- Start
- 2008-10
- Primary completion
- 2010-01
- Completion
- 2010-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tabalumab | Monoclonal antibody | 1 mg | Subcutaneous |
| Subject | Tabalumab | Monoclonal antibody | 3 mg | Subcutaneous |
| Subject | Tabalumab | Monoclonal antibody | 10 mg | Subcutaneous |
| Subject | Tabalumab | Monoclonal antibody | 30 mg | Subcutaneous |
| Subject | Tabalumab | Monoclonal antibody | 60 mg | Subcutaneous |
| Subject | Tabalumab | Monoclonal antibody | 120 mg | Subcutaneous |